<DOC>
	<DOCNO>NCT01876212</DOCNO>
	<brief_summary>Current therapeutic approach available patient advanced-stage melanoma remain inadequate , exist approach include involve immunotherapy cytokine and/or target strategy result disappointingly low rate durable complete response . Correcting immune dysfunction advanced-stage melanoma patient use tyrosine-kinase inhibitor ( TKI ) dasatinib propose relicense patient 's immune system respond optimally specific immunization . The integration antigen express tumor-associated blood vessel cell provide mean selectively target genetically-/antigenically-heterogeneous population tumor cell advanced-stage melanoma patient . This single-center , prospective randomize Phase 2 trial evaluating activity , safety immune effect dasatinib give combination autologous type-1 polarize Dendritic Cell ( αDC1 ) vaccine . The current trial represent randomized Phase 2 study determine activity safety intradermal ( id ) administration αDC1s load mixture six TBVA-derived peptide time , immediately , initial therapy cycle TKI dasatinib . Dasatinib administer standard dose schedule recommend FDA ( 70 mg BID ) . The autologous type-I DC vaccine administer either prior , concomitant , initiation dasatinib administration . All patient receive dasatinib start dose 70 mg twice daily mouth outpatient set approximately every 12 hour , time day . The DC vaccine administer single intradermal injection approximately 10e7 cell , DCs administer day 1 15 every cycle outpatient basis University Pittsburgh Clinical Translational Research Center ( UPCI-CTRC ) . Patients Arm A start dasatinib administration cycle 2 , day 1 ( week 5 ) , patient Arm B start dasatinib administration cycle 1 , day 1 ( week 1 ) . Men woman least 18 year age must HLA-A2+ histologically confirm melanoma metastatic ( Stage IV ) unresectable Stage IIIB/C standard curative palliative measure exist longer effective .</brief_summary>
	<brief_title>Dendritic Cell Vaccines + Dasatinib Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients must HLAA2+ histologically confirm melanoma metastatic ( Stage IV ) unresectable Stage IIIB/C standard curative palliative measure exist longer effective . Patients must measurable disease RECIST 1.1 , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan , MRI , caliper clinical exam . See Section 11 evaluation measurable disease . Patients least 2 subcutaneous , intracutaneous , accessible tumor deposit , lymph node site available biopsy purpose . Patients one biopsiable site amenable 2 biopsy ( pre post ) consider eligible . Prior chemotherapy , immunotherapy , target therapy allow long include dasatinib . Age &gt; 18 year . Because dose adverse event data currently available use dasatinib patient &lt; 18 year age , child exclude study , eligible future pediatric trial . ECOG performance status &lt; 2 ( Karnofsky &gt; 60 % , see Appendix A ) . Life expectancy great 12 week . Patients must normal organ marrow function define : Leukocytes ≥ 3,000/µL absolute neutrophil count ≥ 1,500/µL absolute lymphocyte count ≥ 500/µL platelet ≥ 100,000/µL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional upper limit normal Creatinine ≤ 2.0 X institutional upper limit normal Serum magnesium , potassium adjust ( ionize ) calcium ≥ institutional low limit normal . ( Supplementation electrolytes prior screen allow ) . Sexually active woman men childbearing potential must agree use effective method birth control course study 3 month follow last dose study drug , manner risk pregnancy minimize . Surgical sterilization , intrauterine device barrier method ( e.g . condom and/or diaphragm spermicidal agent ) acceptable form birth control . Women childbearing potential must negative pregnancy test ( serum ) within 7 day prior treatment . A pregnancy test require registration . Women menstruate 2 year consider postmenopausal , thus childbearing potential . Ability understand willingness sign write informed consent document . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . Patients document cKIT mutation . Patients receive investigational agent . Patients know active brain metastasis exclude . Patients treat brain metastasis document stability 4 week eligible . History allergic reaction attribute compound similar chemical biologic composition dasatinib component vaccine administer part study . Women pregnant nursing/breastfeeding . History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Patients currently take medication inhibit platelet function ( i.e. , aspirin , dipyridamole , epoprostenol , eptifibatide , clopidogrel , cilostazol , abciximab , ticlopidine , nonsteroidal antiinflammatory drug ) potential increase risk bleeding dasatinib . Patients currently take anticoagulant ( warfarin , heparin/low molecular weight heparin [ e.g. , danaparoid , dalteparin , tinzaparin , enoxaparin ] ) potential increase risk bleeding dasatinib . Diagnosis unstable angina myocardial infarction within 6 month study entry . Patients currently take one follow drug generally accept risk cause Torsades de Pointes : quinidine , procainamide , disopyramide amiodarone , sotalol , ibutilide , dofetilide erythromycin , clarithromycin chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . Diagnosed suspected congenital long QT syndrome . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) within 30 day prior study registration . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction dasatinib . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>vaccine</keyword>
	<keyword>BRAF</keyword>
</DOC>